Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer

Cancer Letters

Volumn 210, Issue 2, 2004, Pages 189-196

  Yonemura, Yutaka ^a   Endou, Yoshio ^b   Bando, Etsurou ^a   Kuno, Kiyoshi ^a   Kawamura, Taiichi ^a   Kimura, Masashi ^a   Shimada, Tsutomu ^c   Miyamoto, Ken Ichi ^c   Sasaki, Takuma ^b   Sugarbaker, Paul H ^d  

^a SHIZUOKA CANCER CENTER   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Chemotherapy; Docetaxel; Gastric cancer; Intraperitoneal; Peritoneal dissemination

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; DOCETAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER MORTALITY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; INOCULATION; MOUSE; NONHUMAN; NUDE MOUSE; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOEMBRYONIC ANTIGEN; FEMALE; INFUSIONS, PARENTERAL; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

ANIMALIA; MUS MUSCULUS;

EID: 2942585119     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.03.018     Document Type: Article

References (21)

1. Chu Z.D., Lang N.P., Thompson C., Osteen P.K., Westbrook K.C. Peritoneal carcinomatosis in nongynecological malignancy. A prospective study of prognostic factors. Cancer. 63:1989;364-367
2. Cullinan S.A., Moertel C.G., Fleming T.R., Rubin J.R., Krook J.E., Everson L.K., et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. J. Am. Med. Assoc. 253:1985;2061-2067
3. MacDonald J.S., Philip S.S., Woolley P.V., Smythe T., Ueno W., Hoth D., et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann. Intern. Med. 93:1980;533-536
4. Wils J.A., Klein H.O., Wagener D.J., Bleiberg H., Reis H., Korsten F., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9:1991;827-831
5. Ajani J.A., Ota D.M., Jessup J.M., et al. Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer. 68:1991;1501-1506
6. Sugarbaker P.H., Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 58:2000;96-107
7. Sugarbaker P.H., Stuart O.A., Vidal-Jove J., et al. Studies of the peritoneal-plasma barrier after systemic mitomycin C administration. Reg. Cancer Treat. 4:1993;188-194
8. Jacquet P., Sugarbaker P.H. Peritoneal-plasma barrier. Sugarbaker P.H. Peritoneal Carcinomatosis: Principles of Management. 1996;53-63 Kluwer, Boston
9. Markman M. Intraperitoneal chemotherapy. Semin. Oncol. 18:1991;248-254
10. Diaz J.F., Andreu J.M. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry and competition. Biochemistry. 32:1993;2747-2755
11. Debernardis D., Sire E.G., De Feudis P., Virhanskaya F., Valeni M., Russo P., et al. p53 Status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 57:1997;870-874
12. Marchettini P., Stuart A., Mohamed F., Yoo D., Sugarbaker P.H. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother. Parmacol. 49:2002;499-503
13. Dyke D.J., Bissery M.C., Harrison S.D., Waud W.R. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest. New Drugs. 13:1995;1-11
14. Yonemura Y., Endo Y., Fujita H., Fushida S., Bandou E., Taniguchi K., et al. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer. 3:2002;63-70
15. Tanaka M., Obata T., Sasaki T. Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur. J. Cancer. 32:1996;226-230
16. Goel R., Cleary S.M., Horton C., Kirmani S., Abramson I., Kelly C., Howell S.B. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. Natl Cancer Inst. 81:1989;1552-1560
17. O'Dwyer P.J., LaCreta F.P., Daugherty J.P., Hogan M., Rosenblum N.G., O'Dwyer J.L., Comis R.L. Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res. 15:(51):1991;2041-2046
18. Fushida S., Furui N., Kinami S., Ninomiya I., Fujimura T., Nishimura G., et al. Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination. Jpn J. Cancer Chemother. 29:2002;2164-2167
19. Taguchi T., Furue H., Niitani H., et al. Phase 1 clinical trial of RP 56976 (Docetaxel) a new anticancer drug. Jpn J. Cancer Chemother. 21:1994;1997-2005
20. van Tellingen O., Beijnen J.H., Verweij J., Scherrenburg E.J., Nooijen W.J., Sparreboom A. Rapid esterase-sensitive breakdown of polysorbete 80 and its impact on the lasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res. 5:1999;2918-2924
21. Lee S.H., Yoo S.D., Lee K.H. Rapid and sensitive determination of paclitaxel concentration in mouse plasma by high-performance liquid chromatography. J. Chromatogr. Biomed. Sci. 724:1999;357-363